Consequently, targeting prostate cancers characterized by elevated CRP levels or increased PGE-2 production mediated by COX-1/2 with anti-inflammatory or immunomodulatory strategies could serve as a beneficial adjunct. Here, CRP is linked to prostate carcinoma.